China updates drug reimbursement list, agrees price cuts

PM Live

2 December 2019 - Drugs added include AbbVie's Humira and Roche's Perjeta.

Chinese regulators have added 70 new medicines to the country’s National Reimbursement Drug List (NRDL), and has agreed an average of 61% in price cuts with pharma companies.

The key drugs which have been added to the list include AbbVie’s blockbuster drug Humira (adalimumab), Novartis’ dermatitis drug Xolair (omalizumab) and Roche’s HER2 breast cancer treatment Perjeta (petuzumab).

Read PM Live article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Market access , Funding , China